Loading menu…

Clinical Features and Outcome of Inflammatory Breast Cancer in Moroccan Population: Experience of Oncology Department of National Institute of Rabat

§ National Institute of Oncology
‡ Department of Medical Oncology, National Institute o...

Send Message

To: Author

Clinical Features and Outcome of Inflammatory Breast Cancer in Moroccan Population: Experience of Oncology Department of National Institute of Rabat

Article Fingerprint

ReserarchID

18K8T

Clinical Features and Outcome of Inflammatory Breast Cancer in Moroccan Population: Experience of Oncology Department of National Institute of Rabat Banner

Key Research Insights

Synthesized scholarly intelligence & interactive research assistant
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
Reading Preferences
Font Size
Line Spacing
Background

References

29 Cites in Article
  1. 1. Bouzaiene Boussen H,Dhiab Ben Hassouna J,Benna Khomsi F,clinical .Cancer (2010). Inflammatory breast cancer in Tunisia: epidemiological and clinical trends.
  2. 2. Mourali N,Muenz LR,Tabbane F,Belhassen S,Bahi J (1980). Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer, 46(12), 27412746.
  3. 3. Shine Chang,Sheryl Parker,Tuan Pham,Aman Buzdar,Stephen Hursting (1998). Inflammatory breast carcinoma incidence and survival. Cancer, 82(12), 2366-2372.
  4. 4. Hance KW,Anderson WF,Devesa SS,Young HA,Levine PH (2005). Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute J Natl Cancer Inst. 2005 Jul 6, 97(13), 966-975.
  5. 5. Glenn Lawson JS,Ye Salmons B,Moody Heng B (2010). Mouse Mammary Tumor Virus–like Sequences in Human Breast Cancer. 2010 May 1, 70(9), 3576-3585.
  6. 6. S. Singletary,Massimo Cristofanilli (2008). Defining the Clinical Diagnosis of Inflammatory Breast Cancer seminars in oncology. Seminars in Oncology, 35(1), 7-10.
  7. 7. William Anderson,Catherine Schairer,Bingshu Chen,Kenneth Hance,Paul Levine (2005). Anderson, Catherine Schairer, Bingshu E Chen, Kenneth W Hance, Paul H Levine Epidemiology of inflammatory breast cancer Breast Disease Breast Dis. Breast Disease, 22, 9-23.
  8. 8. (2011). International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol, 22(3), 515-523.
  9. 9. Paradiso A,Tommasi S,Brandi M,Marzullo F,Simone G (1989). Cell kinetics and hormonal receptor status in inflammatory breast carcinoma: Comparison with locally advanced disease Cancer. Cancer, 64(9)
  10. 10. William Anderson,Kenneth Chu,Shine Chang (2003). Inflammatory Breast Carcinoma and Noninflammatory Locally Advanced Breast Carcinoma: Distinct Clinicopathologic Entities?. Journal of Clinical Oncology, 21(12), 2254-2259.
  11. 11. (2008). Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry. BMC Cancer, 8, 28.
  12. 12. Chaher N,Arias-Pulido H,Terki N,Qualls C,Bouzid K,Verschraegen C (2012). Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients Breast Cancer Res Treat. 2012 Jan, 131(2), 437-444.
  13. 13. Gabillot Guerin M,JP MC Mathieu,N. M Spielmann (1989). Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance International Journal of Cancer Volume 43. International Journal of Cancer, 43(2), 201-208.
  14. 14. (2004). p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer. Clinical Cancer Res, 10, 6215.
  15. 15. Kleer CG,Van KL,Braun T,Merajver SD (2001). Persistent E-Cadherin Expression in Inflammatory Breast Cancer. Modern Pathoogy, 14(5), 458-464.
  16. 16. PB CG Colpaert,A. I Benoy,F. Van Roy (2003). Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression British Journal of Cancer 2003. British Journal of Cancer, 88(5), 718-725.
  17. 17. L. Kenneth,Seena van Golen,Davies,Fen Zhi,Yunfang Wu,Corazon Wang (1999). van Golen, Seena Davies, Zhi Fen Wu, YunFang Wang, Corazon D Bucana, Holly Root, : A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory Breast cancer), and Rhoc GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res, 5(9), 2511-2519.
  18. 18. Yamauchi H,Woodward WA,Valero V,Alvarez RH,Lucci A,Buchholz TA Inflammatory Breast Cancer: What We Know and What We Need to Learn. The Oncologist, 17(7), 891-899.
  19. 19. T. Naoto,Aman Ueno,Sonja Buzdar,Frederick Singletary,Marsha Ames,McNeese (1997). Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemotherapy and Pharmacology, 40(4), 321-329.
  20. 20. Massimo Cristofanilli,Ana Gonzalez-Angulo,Aman Buzdar,Shu-Wan Kau,Debbie Frye,Gabriel Hortobagyi (2004). Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M D Anderson Cancer Center experience Clin Breast Cancer. Clinical Breast Cancer, 4(6), 415-419.
  21. 21. Eiermann Gianni L,Manikhas Semiglazov V,Lluch A,locally cancer,The trial (2010). Lancet. The Lancet, 375(9712), 377-384.
  22. 22. Bernard Chevallier,Bernard Asselain,Antoine Kunlin,Corinne Veyret,Philippe Bastit,Yvon Graic (1987). Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer, 60(4), 897-902.
  23. 23. I. Faneyte,J. Schrama,J. Peterse,P. Remijnse,S. Rodenhuis,M. van de Vijver (2003). Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ.Breast cancer response to neoadjuvant chemotherapy : predictive markers and relation with outcome. Cancer, 88, 406-412.
  24. 24. J. Eur (1992). E Belembaogo, V Feillel, P Chollet, H Cure, P Verrelle, F Kwiatkowski, Neoadjuvant chemotherapy in 126 operable breast cancers. Cancer 1992; 28A, 896-900.
  25. 25. Ames Smith TL,Dhingra Hunt KK (1999). Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy. J Clin Oncol, 17, 460-469.
  26. 26. Robertson FM,Bondy M,Yang W,Yamauchi H,Wiggins S,Kamrudin S (2010). Inflammatory breast cancer: the disease, the biology, the treatment, CA Cancer J Clin. 2010 Nov-Dec, 60(6), 351-375.
  27. 27. C. Colpaert,P. Vermeulen,L. Dirix,Van Marck,E. (2003). Microvessel density, expression of oestrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast Cancer Clin Cancer Res. Clin Cancer Res, 9(10 Pt 1), 3815-3816.
  28. 28. Pierga JY,Petit T,Delozier T,Ferrero JM,Campone M,Gligorov J (2012). Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study Lancet Oncol. 2012 Apr, 13(4), 375-384.
  29. 29. S. Rabiya,Tuma (2012). ALK gene amplified in most inflammatory breast cancers. JNCI J Natl Cancer Inst, 104(2), 87-88.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Ouziane I MD, Imane Ouziane, Bensouda Y MD, HM’rabti MD, Elomrani F MD, Elismaili N MD, Laanaz S MD, Elyacoubi H MD, Berrada N MD, Boutayeb S MD, Errihani H. 2015. "Clinical Features and Outcome of Inflammatory Breast Cancer in Moroccan Population: Experience of Oncology Department of National Institute of Rabat". Global Journal of Medical Research - E: Gynecology & Obstetrics GJMR-E Volume 15 (GJMR Volume 15 Issue 23 (E2)).

More Citation Formats

Download Citation

Issue Cover
GJMR Volume 15 Issue 23 (E2)
Pg. 1-8
Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-E Classification NLMC Code: WP 840
Version of record
v1.2

Issue date
July 6, 2015

Language
English
Order Article Reprint
Experience in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 1.1K
Total Downloads: 44
All Trends

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Clinical Features and Outcome of Inflammatory Breast Cancer in Moroccan Population: Experience of Oncology Department of National Institute of Rabat

Imane Ouziane
Imane Ouziane <p>National Institute of Oncology</p>
Elomrani MD
Elomrani MD
Elismaili MD
Elismaili MD

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X